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background: Human immunodeﬁciency virus (HIV) is prevalent in many countries where small-for-gestational age (SGA) and pre-
mature delivery are also common. However, the associations between maternal HIV, preterm delivery and SGA infants remain unclear.
We estimate the prevalence of SGA and preterm (,37 weeks) births, their associations with antenatal maternal HIV infection and their
contribution to infant mortality, in a high HIV prevalent, rural area in South Africa.
methods: Data were collected, in a non-randomized intervention cohort study, on all women attending antenatal clinics (2001–2004),
before the availability of antiretroviral treatment. Newborns were weighed and gestational age was determined (based on last menstrual
period plus midwife assessment antenatally). Poisson regression with robust variance assessed risk factors for preterm and SGA birth,
while Cox regression assessed infant mortality and associated factors.
results: Of 2368 live born singletons, 16.6% were SGA and 21.4% were preterm. HIV-infected women (n ¼ 1189) more commonly had
SGA infants than uninfected women (18.1 versus 15.1%; P ¼ 0.051), but percentages preterm were similar (21.8 versus 20.9%; P ¼ 0.621).
After adjustment for water source, delivery place, parity and maternal height, the SGA risk in HIV-infected women was higher [adjusted
relative risk (aRR) 1.28, 95% conﬁdence interval (CI): 1.06–1.53], but the association between maternal HIV infection and preterm delivery
remained weak and not signiﬁcant (aRR: 1.07, 95% CI: 0.91–1.26). In multivariable analyses, mortality under 1 year of age was signiﬁcantly
higher in SGA and severely SGA than in appropriate-for-gestational-age infants [adjusted hazard ratio (aHR): 2.12, 95% CI: 1.18–3.81 and
2.77, 95% CI: 1.56–4.91], but no difference in infant mortality was observed between the preterm and term infants (aHR: 1.18 95% CI:
0.79–1.79 for 34–36 weeks and 1.31, 95% CI: 0.58–2.94 for ,34 weeks).
conclusions: Maternal HIV infection increases the risk of SGA, but not preterm births, in this cohort.
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Introduction
Low birthweight (LBW) is a signiﬁcant risk factor for infant mortality
(Bhutta et al., 2005). LBW is commonly deﬁned at a cut-off of
2500 g, and may be due to preterm delivery, growth restriction or
both (Euser et al., 2008). In developed countries, LBW rates are
low and caused mainly by prematurity while in developing countries,
where the prevalence of LBW is .10% (Costello et al., 2001),
LBW is often due to intrauterine growth restriction (IUGR) and
often associated with small-for-gestational age (SGA) (Villar and
Belizan, 1982; Kramer, 1987a,b). Prematurity SGA have heteroge-
neous etiologies (Rayco-Solon et al., 2005), and different outcomes
for the infant (Verhoeff et al., 2001; Zeitlin et al., 2001; Rayco-Solon
et al., 2005); SGA infants have poorer outcomes than
appropriate-for-gestational age (AGA) infants, especially if they are
preterm (Zeitlin et al., 2001). SGA is based on the percentile of the
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our study. Factors associated with SGA and preterm delivery
include socio-economic status, short maternal stature and low parity
(Kramer, 1987a,b; Verhoeff et al., 2001; Zeitlin et al., 2001). In devel-
oping country settings, it is important to understand factors associated
with preterm births and SGA and their contribution to infant mortality,
so that limited resources can be directed at those most at risk and so
that the Millennium Development goal 4 aimed at reducing under-5
mortality by two-thirds between 1990 and 2015, can be achieved.
Human immunodeﬁciency virus (HIV) is highly prevalent in many of
the countries where SGA and premature delivery are also common,
and maternal HIV has been associated with adverse pregnancy out-
comes such as spontaneous abortions, LBW and stillbirths (Langston
et al., 1995; Rollins et al., 2007). However, the detail of associations
between maternal HIV, preterm delivery and SGA infants remains
unclear. In high HIV prevalence areas, some studies have reported a
70% increased risk of preterm delivery and a 40% increased risk of
SGA associated with HIV (Bulterys et al., 1994; Taha et al., 1995),
but this is not conﬁrmed in other studies (Temmerman et al., 1994;
Verhoeff et al., 2001). These inconsistent ﬁndings may be due to
the lack of a standardized deﬁnition of SGA, difﬁculty in assessing ges-
tational age or not adjusting for confounding factors (Brocklehurst and
French, 1998; Verhoeff et al., 2001). The inability to obtain precise in-
formation on pregnancy duration in resource-limited settings has
resulted in the use of birthweight as a proxy for gestational age in
some studies (Temmerman et al., 1990; Taha et al., 1995).
However, although birthweights are routinely recorded in health facil-
ities, these are often not recorded in settings where a substantial
number of births occur at home.
In this study, we estimate the prevalence of SGA and preterm births
in a HIV prevalent, rural area in South Africa and evaluate the effect of
maternal HIV infection on the risk of SGA or preterm births; we
further quantify the contribution of SGA and preterm birth to infant
mortality.
Materials and Methods
This vertical transmission study (VTS) enrolled HIV-infected and
-uninfected pregnant women in nine antenatal clinics in two sites, the
largest in rural Umkhanyakude district, northern KwaZulu-Natal and the
other outside Durban, South Africa (Coovadia et al., 2007; Bland et al.,
2010). Recruitment was from August 2001 to September 2004 with
mothers and children followed for 2 years post-natally. Initially, all
HIV-infected women and a systematic sample of uninfected women
were enrolled in the study. However from July 2003, all women attending
antenatal visits were offered enrolment before HIV testing. All pregnant
women were tested for HIV and counselled at the antenatal clinic, by
lay HIV counsellors, on infant feeding options according to the World
Health Organization (WHO)/United Nations programme on AIDS
recommendations current at that time (Bland et al., 2007). All
HIV-infected women and their infants were offered single-dose nevirapine,
but at the time of the study, antiretroviral treatment was not available
through the public health services in South Africa. The study was approved
by the Biomedical Research Ethics Committee of the University of
KwaZulu-Natal.
Gestational age at delivery was determined on the basis of last men-
strual period (collected at antenatal visits by trained study staff), unless
adjusted by midwife assessment on the basis of a clinical assessment.
Birthweight was measured by study staff or taken from clinic registers
within 72 h of birth. For infants born at home, mothers brought their
infant to the clinic the following day (or within 72 h) for immunization
(BCG and polio), weighing and registration to obtain a road-to-health
card (RTHC); this is the general practice in South Africa since without
the RTHC, children cannot access public services such as clinics or
school. These infants were weighed by the study staff. However, if
women delivered in facilities outside the study area or study staff were
not available, we used the weight documented by the Department of
Health staff on the RTHC (Rollins et al., 2007).
Infants attended monthly clinic visits with a study nurse, scheduled from
6 weeks to 9 months of age, and thereafter quarterly to 24 months. All
study clinic assistants who carried out anthropometric measurements at
each visit received standardized anthropometry instructions with regular
in-service training also given to ensure strict adherence to the techniques.
The clinic manager conducted quality assurance checks of measurement
techniques throughout the study. The same measuring equipment was
used at all of the clinics with precision within 10 g for newborns while
for older children, portable electronic weighing scales with taring capability
and a precision to 100 g (UNICEF electronic scale 890) was used as
recommended by WHO (de Onis et al., 2004). At approximately
weekly intervals, the clinic manager checked calibration using standard
metal weights. Further, each child had two weights recorded and if their
difference was .100 g, a third measurement was taken and the two
weights within 100 g were recorded; the mean value was calculated for
this analysis (de Onis et al., 2004).
Dried blood spot (DBS) samples were collected from all HIV-exposed
newborn infants within 72 h of birth, and then at each scheduled clinic visit
to determine their HIV status. HIV status was established by quantitative
HIV RNA assay with a sensitivity of 80 copies/ml (equivalent to
1600 copies per 50 ml DBS) (Bland et al., 2010). Infants were considered
to be perinatally infected if the DBS sample taken at 4–8 weeks was posi-
tive, post-natally infected if the 4–8-week sample was negative and any
subsequent sample was positive or infected with ‘timing unknown’ if the
ﬁrst sample was taken after 8 weeks and was positive.
In the antenatal period, socio-demographic and past and current preg-
nancy data were collected using structured questionnaires; post-natally,
daily infant morbidity and feeding practices were documented at weekly
intervals, and maternal weights, mid-upper arm circumference (MUAC)
and height were measured (Bland et al., 2010). For these analyses, the
weight and MUAC taken at 6 weeks post-delivery were used.
Deﬁnitions
Antenatal maternal HIV status was classiﬁed into HIV positive and nega-
tive; maternal CD4 count was measured in all HIV-positive women.
LBW was deﬁned as ,2500 g (Kramer, 1987a,b). Infants were classiﬁed
as preterm if the gestational age at birth was ,37 completed weeks,
and as SGA if below the 10th percentile of the birthweight-for-gestational
age, as recommended by the WHO (WHO, 1995), with the US
population-based reference used as the standard for comparability of
the prevalence rates of SGA, and the potential effect of maternal HIV in-
fection on SGA, with previous studies elsewhere in Africa (Alexander
et al., 1996). To assess severely small-for-gestational-age infants, risk asso-
ciations were further analyzed at a 3% cutoff (Oken et al., 2003). Size for
gestational age was therefore categorized into three groups based on per-
centiles: AGA, ≥10%; SGA, 3 ≤ 10% and ,3%, severely SGA. We only
included singleton live births, given the increased risk of LBW and prema-
ture delivery for multiple birth; we also excluded stillbirths as four-ﬁfths
had missing birthweights. Place of delivery was classiﬁed into health facility
and home. Parity was classiﬁed so as to compare primiparae with multip-
arae (Mansour et al., 2002) and was categorized as 0, 1–3 or ≥4. Based
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peri-urban or urban, as most people in this setting are likely to attend
their nearest clinic, with the median travel time of 81 min (Tanser,
2006). Neonatal mortality was deﬁned as a death in the ﬁrst 4 weeks of
life (Lawn et al., 2005), while infant mortality was deﬁned as the death
by 12 months of age.
Statistical analysis
Data were analysed using Stata Version 11.2 (STATA Corps, College
Station, TX, USA). Differences between HIV-infected and -uninfected
women were assessed using t-test for continuous variables with normal
distribution, x
2 test for categorical variables and Fisher’s exact test if the
numbers were small. Poisson regression, with a value of one attributed
to each participant’s follow-up time to obtain prevalence ratio estimates
(done on all subjects and then separately among the HIV-positive and HIV-
negative mothers), was used to assess factors associated with SGA and
preterm delivery. To minimize overestimation of the relative risk when
using Poisson regression for a categorical covariate of interest, a robust
variance procedure was used (Lin and Wei, 1989). This method was con-
sidered to be a better alternative than the logistic regression for analysis of
cross-sectional data, with the latter producing higher estimates than the
former (Coutinho et al., 2008). For ease of comparison with other
studies, we repeated our analyses using the conventional binary logistic re-
gression and found essentially similar results to those presented here using
Poisson regression. Variables were considered for inclusion in the multi-
variable model. Goodness-of-ﬁt tests, assessed using the likelihood-based
Akaike information criteria (AIC), were used to determine the variables
that signiﬁcantly improved the ﬁnal Poisson models’ ﬁt (Bruin, 2006).
Mortality by maternal HIV status and SGA was assessed using Kaplan–
Meier survival analysis. Follow-up time was computed as time from birth to
withdrawal, loss to follow-up, migration or death if before the ﬁrst year of
life, whichever came ﬁrst, allowing for child’s HIV status as a time-varying
variable for infant mortality analyses. Risk factors for infant mortality were
assessed in univariable and multivariable Cox regression models with child
HIV infection as a time-dependent variable; for the adjusted model, vari-
ables with a statistically signiﬁcant association univariately were included
in addition to three included (parity, maternal age and education) a
priori (Ndirangu et al., 2010).
Results
There were 2811 live births in the cohort; 350 live births were
excluded from the analysis: 76 (2.7%) had improbably high gestational
age, 2 (0.1%) were missing birthweight and gestational age, 9 (0.3%)
were missing gestational age only, 187 (6.7%) were missing birthweight
data only and 76 (2.7%) had an improbable birthweight/gestational
age combination (Fig. 1). A further 93 (3.3%) live births were excluded
either because they were multiple births (86) or due to indeterminate
maternal antenatal HIV status (7). A total of 2368 live born infants
(1189 of HIV-infected and 1179 of HIV-uninfected women) were
thus included in the analyses. HIV-uninfected women were signiﬁcantly
younger than infected women, more likely to be enrolled from rural
clinics and less likely to have infants with LBW and SGA (Table I).
HIV-infected women did not differ signiﬁcantly from uninfected
women with respect to place or type of delivery, gestational age or
water source.
Prevalence of SGA and preterm deliveries
The median birthweight was 3100 g (inter-quartile range: 2850–3400)
and 198 (8.4%) infants were LBW. Overall, 506 (21.4%) infants were
born preterm, of these 188 (37%) were born at 36 weeks and nearly
one-third were ,34 weeks gestational age and 36 (7.1%) preterm
Figure 1 Study population. *Improbably high gestational age was .46 weeks.
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two-ﬁfths of these were severely growth restricted and 36 (9.2%) of
the SGA births were preterm. The percentage of SGA infants was
higher for HIV-positive than for HIV-negative women (18.1 and
15.1% respectively, P ¼ 0.051). Similarly, the proportion of preterm
deliveries was slightly higher in HIV-positive than in HIV-negative
women, although this was not statistically signiﬁcant (21.8 and
20.9%, respectively, P ¼ 0.621).
Stratifying by the child’s HIV status: 26 (23.6%) of the perinatally
infected, 9 (15.8%) of the post-natally infected and 318 (16.3%) of
the uninfected children were SGA, P ¼ 0.378, while 26 (23.6%), 13
(22.8%) and 417 (21.4%), respectively, were preterm, P ¼ 0.722.
Risk factors for SGA and prematurity
Table II presents the overall risk factors for SGA and prematurity. The
probability of an SGA infant signiﬁcantly increased with maternal
HIV-infection after adjusting for other factors, known to be associated
with SGA risk. Additionally, compared with the relevant reference cat-
egories, infants residing in a household without piped water (a proxy
indicator of lower socio-economic status) had a signiﬁcantly higher
probability of being SGA, as were ﬁrst born, those born at home,
and those whose mother’s height at birth was below the study popu-
lation mean.
Among HIV-positive mothers, those residing in a household without
piped water (adjusted prevalence ratio (aRR): 1.34, 95% CI: 1.05–
1.71), delivering at home (aRR: 1.59, 95% CI: 1.17–2.16), delivering
for the ﬁrst time (aRR: 1.59, 95% CI: 1.24–2.04) or of shorter
stature (aRR: 1.81, 95% CI: 1.21–2.68) were at a signiﬁcantly higher
probability of having an SGA infant. Additionally, infants of HIV-
positive mothers with CD4 counts below 200 cells/mm
3 had a
higher probability of being SGA (aRR: 1.43, 95% CI: 1.00–2.07, P ¼
0.053). In HIV-negative mothers, after adjusting for all other factors
in Table II, parity was the only factor signiﬁcantly associated with
SGA, with ﬁrst born infants having a higher probability of being SGA
(aRR: 1.97, 95% CI: 1.42–2.73).
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Table I Maternal and infant characteristics by maternal HIV status.
Variable HIV infected (n 5 1189) HIV uninfected (n 5 1179) Total (n 5 2368) P
Enrollment clinic
Rural 513 (43.1%) 642 (54.5%) 1155 (48.8%) ,0.001
Peri-urban 448 (37.7%) 355 (30.1%) 803 (33.9%)
Urban 228 (19.2%) 182 (15.6%) 410 (17.3%)
Place of delivery
Home/other
a 141 (11.8%) 139 (11.8%) 280 (11.8%) 0.959
Hospital/clinic 1048 (88.1%) 1040 (88.2%) 2088 (88.2%)
Type of delivery
Cesarean 166 (13.9%) 149 (12.6%) 315 (13.3%) 0.638
Vaginal 1022 (86.0%) 1029 (87.3%) 2051 (86.6%)
Missing 1 (0.1%) 1 (0.1%) 2 (0.1%)
Birthweight (g)
≥2500 1072 (90.2%) 1098 (93.1%) 2170 (91.6%) 0.009
,2500 117 (9.8%) 81 (6.9%) 198 (8.4%)
Gestational age
≥37 weeks 930 (78.2%) 932 (79.1%) 1862 (78.6%) 0.963
34 to ,37 weeks 183 (15.4%) 173 (14.7%) 356 (15.0%)
32 to ,34 weeks 47 (4.0%) 45 (3.8%) 92 (3.9%)
,32 weeks 29 (2.4%) 29 (2.4%) 58 (2.5%)
Size for gestation
≥10% 974 (81.9%) 1001 (84.9%) 1975 (83.4%) 0.051
3t o,10% 121 (10.2%) 105 (8.9%) 226 (9.5%)
,3% 94 (7.9%) 73 (6.2%) 167 (7.1%)
Maternal variables (median, IQR)
Age (years) 25.1 (21.6–29.6) 21.8 (19.1–27.7) 23.6 (20.1–28.8) ,0.001
Weight 61.8 (55.7–69.5) 62.6 (56.3–70.4) 62.2 (56.0–69.8) 0.017
Height 158.1 (154.2–162.6) 158.5 (154.9–163.0) 158.4 (154.5–162.8) 0.060
BMI 24.9 (22.4–27.6) 24.6 (22.6–27.8) 24.7 (22.5–27.7) 0.951
MUAC 27.1 (25.0–29.5) 27.1 (25.0–29.7) 27.1 (25.0–29.6) 0.243
P indicates the statistical difference between HIV infected and HIV uninfected.
aOther place of delivery refers to deliveries on the way to hospital or clinic.
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Table II Risk factors for SGA and preterm birth (n 5 2368).
Variable Overall live
births [n (%)]
SGA
unadjusted RR
(95% CI)
P SGA
adjusted RR
(95% CI)
P Preterm
unadjusted RR
(95% CI)
P Preterm
adjusted RR
(95% CI)
P
Infant gender
Female 1188 (50.2) 1.00 1.00
Male 1178 (49.8) 1.09 (0.91–1.31) 0.329 1.01 (0.86–1.18) 0.909
Area
Rural 1161 (49.0) 1.00 1.00
Peri-urban 807 (34.1) 0.92 (0.75–1.13) 0.424 0.90 (0.63–1.28) 0.552
Urban 400 (16.9) 1.00 (0.78–1.28) 0.994 0.91 (0.58–1.42) 0.675
Water source
Piped 1601 (67.6) 1.00 1.00 1.00
Non-piped 706 (29.8) 1.29 (1.07–1.56) 0.008 1.26 (1.04–1.51) 0.017 1.85 (0.71–2.02) 0.077
Missing data 61 (2.6) 0.73 (0.36–1.49) 0.392 0.71 (0.35–1.43) 0.337 1.31 (0.88–1.95) 0.186
Toilet type
Flush 398 (16.8) 1.00 1.00
Non-ﬂush 1378 (58.2) 0.99 (0.76–1.27) 0.910 1.13 (0.90–1.41) 0.284
None 531 (22.4) 1.36 (1.02–1.79) 0.032 1.15 (0.89–1.49) 0.276
Missing data 61 (2.6) 0.72 (0.35–1.50) 0.387 1.52 (0.98–2.36) 0.058
Delivery place
Hospital/
clinic
2088 (88.2) 1.00 1.00 1.00 1.00
Home/
other
208 (11.8) 1.34 (1.05–1.72) 0.018 1.48 (1.16–1.90) 0.002 1.36 (1.11–1.67) 0.004 1.38 (1.12–1.69) 0.002
Parity
1–3 1155 (48.8) 1.00 1.00 1.00
0 1018 (43.0) 1.58 (1.30–1.91) ,0.001 1.71 (1.41–2.07) ,0.001 1.02 (0.87–1.19) 0.840
≥4 195 (8.2) 1.26 (0.88–1.78) 0.203 1.24 (0.87–1.77) 0.241 0.76 (0.54–1.06) 0.106
Maternal age
.30 years 509 (21.5) 1.00 1.00 1.00
20–30 years 1275 (53.8) 0.96 (0.76–1.22) 0.763 1.18 (0.95–1.45) 0.133 1.15 (0.92–1.43) 0.196
,20 years 582 (24.6) 1.10 (0.85–1.43) 0.458 1.31 (1.03–1.65) 0.025 1.30 (1.02–1.66) 0.033
Missing data 2 (0.1)
Maternal HIV
HIV negative 1179 (49.8) 1.00 1.00 1.00 1.00
HIV positive 1189 (50.2) 1.20 (1.00–1.44) 0.052 1.28 (1.06–1.53) 0.009 1.39 (0.89–1.21) 0.621 1.07 (0.91–1.26) 0.380
Maternal education
No
education
139 (5.9) 1.00 1.00
Some
primary
811 (34.2) 1.05 (0.58–1.93) 0.858 1.74 (0.76–3.97) 0.189
Secondary
and tertiary
1418 (59.9) 1.08 (0.60–1.94) 0.794 1.72 (0.77–3.85) 0.186
Maternal weight
≥Mean 823 (33.5) 1.00 1.00 1.00
,Mean 1039 (42.3) 1.44 (1.15–1.79) 0.002 1.35 (1.13–1.62) 0.001 1.28 (1.07–1.54) 0.008
Missing data 592 (24.1) 1.47 (1.15–1.89) 0.002 1.04 (0.83–1.29) 0.741 1.01 (0.81–1.27) 0.893
Maternal height
≥Mean 661 (26.9) 1.00 1.00 1.00
,Mean 672 (27.4) 1.33 (1.02–1.74) 0.032 1.36 (1.05–1.77) 0.020 1.11 (0.91–1.37) 0.297
Missing data 1121 (45.7) 1.43 (1.12–1.82) 0.003 1.41 (1.11–1.79) 0.005 0.95 (0.78–1.15) 0.591
Continued
1850 Ndirangu et al.Additional analyses were carried out to assess the effect of maternal
HIV infection on the risk of delivering severely growth-restricted
infants (,3% birthweight-for-gestational age percentile). Adjusting
for the risk factors in the ﬁnal model, infants born to HIV-positive
mothers had higher probability of severe growth restriction than
those of HIV-negative mothers, although this did just not reach statis-
tical signiﬁcance due to lack of statistical power (aRR: 1.33, 95% CI:
0.98–1.79; P ¼ 0.067).
In both univariate and multivariable analyses, the probability of
preterm delivery was not signiﬁcantly associated with maternal HIV in-
fection (Table II). However, probability of preterm delivery was signiﬁ-
cantly higher in infants born at home, as well as in those born to
mothers aged less than 20 years and mothers whose maternal
weight at birth was less than the population mean. Among HIV-
positive women, delivery place was the only statistically signiﬁcant vari-
able, with children born at home having signiﬁcantly higher probability
of being preterm (aRR: 1.46, 95% CI: 1.11–1.93). Among HIV-
negative women, maternal weight at birth was the only signiﬁcant vari-
able, with children born to mothers whose weight was below the
population mean having a signiﬁcantly higher probability of being
preterm (aRR: 1.31, 95% CI: 1.01–1.71).
Additional analyses showed that maternal HIV infection was not
associated with severe prematurity (,34 weeks), after adjusting for
other risk factors (aRR: 1.08, 95% CI: 0.78–1.50; P ¼ 0.628).
Mortality
Overall, 5.8% (137/2368) infants died in the ﬁrst year of life: 9.3%
(111/1189) of infants of HIV-positive mothers and 2.2% (26/1179)
of infants of HIV-negative mothers (P , 0.001). Infants born to HIV-
positive women were at signiﬁcantly higher risk of mortality compared
with those of HIV-negative women (IMR, 93.4 and 22.1 per 1000 live
births, P , 0.001). Additionally, HIV infected infants were also at a sig-
niﬁcantly higher mortality risk that uninfected infants (IMR 370.7 and
27.2 per 1000 live births, P , 0.001). Crude neonatal and infant mor-
tality rates did not differ signiﬁcantly between term and preterm births:
6.4 and 3.9 per 1000 live births, P ¼ 0.522 for neonates and 56.4 and
63.2 per 1000 live births, P ¼ 0.561 for infants respectively.
However, both crude neonatal and infant mortality rates differed
signiﬁcantly between AGA and SGA infants. SGA neonates had a mor-
tality rate of 20.4 per 1000 live births, 6-fold higher than those AGA at
3.0 per 1000 live births, P , 0.001. Infant mortality rates among SGA
infants was 101.8 per 1000 live births, double the rate among AGA
infants at 49.1 per 1000 live births, P , 0.001. We estimated that at
age 12 months, 16% of SGA and 10% of AGA infants (P ¼ 0.008)
of HIV-positive mothers will have died and 5% of SGA and 2.5% of
AGA infants (P ¼ 0.079) of negative mothers will have died (Fig. 2).
Factors associated with infant mortality
Table III shows the risk factors for all children in the cohort irrespect-
ive of maternal HIV status. The CD4 count variable includes 1179
HIV-negative mothers classiﬁed as ‘missing’. The 2368 infants were fol-
lowed up for a total of 25 305 child-months over their ﬁrst year of life.
Overall, compared with those AGA, SGA infants had a 2-fold signiﬁ-
cantly increased hazard of death; and severely growth-restricted
infants (,3% percentile) had higher hazards of mortality than those
with less severe growth restriction (Table III). Overall, preterm
infants had a slightly increased risk of death; this did not reach statis-
tical signiﬁcance in either univariate or multivariate analyses. Lower
maternal age was associated with a signiﬁcantly increased hazard
and women with some formal education had a reduced hazard of
infant death.
Infants of HIV-positive mothers had a 3-fold signiﬁcantly increased
hazard of death; those whose mothers had antenatal CD4 counts
,200 cells/mm
3 had a 2-fold signiﬁcantly increased hazard of
death compared with those whose mothers had CD4 counts of at
Figure 2 Estimated infant mortality by 12 months of age by mater-
nal HIV status and size for gestational age.
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Table II Continued
Variable Overall live
births [n (%)]
SGA
unadjusted RR
(95% CI)
P SGA
adjusted RR
(95% CI)
P Preterm
unadjusted RR
(95% CI)
P Preterm
adjusted RR
(95% CI)
P
Maternal MUAC
≥Mean 789 (32.2) 1.00 1.00
,Mean 1039 (42.3) 1.33 (1.06–1.67) 0.013 1.38 (1.15–1.66) 0.001
Missing data 626 (25.5) 1.39 (1.09–1.78) 0.009 1.10 (0.88–1.37) 0.418
RR, relative risk.
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3, when categorizing HIV-negative mothers as
‘missing’.
Overall, 8.7% (206/2368) of infants were HIV infected in the ﬁrst
year of life. Of the 109 perinatally infected infants, 24 (22.0%) were
SGA and 27 (24.8%) were preterm (P ¼ 0.562). The 206 HIV-infected
infants were at a signiﬁcantly increased risk of mortality compared with
those who were HIV uninfected, allowing for child HIV status as a
time-varying variable (Table III).
.............................................................................................................................................................................................
Table III Risk factors for infant mortality (n 5 2368).
Variable Overall live births [n (%)] Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Gestational age
≥37 weeks 1862 (78.6) 1.00 1.00
34–36 weeks 356 (15.1) 1.10 (0.69–1.74) 0.688 1.18 (0.79–1.79) 0.423
,34 weeks 150 (6.3) 1.17 (0.54–2.55) 0.685 1.31 (0.58–2.94) 0.509
Size for gestation
≥10% (AGA) 1975 (83.4) 1.00 1.00
3t o,10% (SGA) 226 (9.5) 2.27 (1.29–4.02) 0.004 2.12 (1.18–3.81) 0.012
,3% (SGA) 167 (7.1) 3.91 (2.31–6.63) ,0.001 2.77 (1.56–4.91) ,0.001
Area
Rural 1161 (49.0) 1.00 1.00
Peri-urban 807 (34.1) 0.86 (0.55–1.33) 0.496 0.73 (0.47–1.14) 0.172
Urban 400 (16.9) 0.28 (0.11–0.69) 0.006 0.25 (0.10–0.67) 0.004
Parity
1–3 1155 (48.8) 1.00 1.00
0 1018 (43.0) 1.09 (0.72–1.67) 0.666 0.94 (0.57–1.57) 0.824
≥4 195 (8.2) 0.49 (0.17–1.36) 0.170 0.71 (0.23–2.22) 0.559
Maternal age
.30 years 509 (21.5) 1.00 1.00
20–30 years 1275 (53.8) 1.62 (0.90–2.92) 0.108 1.59 (0.81–3.12) 0.179
,20 years 582 (24.6) 1.59 (0.83–3.06) 0.165 2.34 (1.01–5.43) 0.047
Missing data 2 (0.1)
Maternal education
No education 139 (5.9) 1.00 1.00
Some primary 811 (34.2) 0.53 (0.25–1.12) 0.097 0.28 (0.13–0.61) 0.002
Secondary and tertiary 1418 (59.9) 0.60 (0.30–1.21) 0.155 0.37 (0.17–0.80) 0.011
Child HIV infection status
Uninfected 1945 (82.1) 1.00 1.00
Perinatally infected 109 (4.6) 24.39 (15.10–39.39) ,0.001 18.43 (10.40–32.65) ,0.001
Post-natally infected 57 (2.4) 5.42 (2.56–11.48) ,0.001 5.06 (2.32–11.01) ,0.001
Infected, timing unknown 40 (1.7) 12.04 (4.32–33.53) ,0.001 7.43 (2.56–21.60) ,0.001
Missing data 217 (9.2) 5.15 (2.42–10.91) ,0.001 5.02 (2.35–10.73) ,0.001
Maternal HIV status
HIV negative 1179 (49.8) 1.00
HIV positive 1189 (50.2) 3.02 (1.91–4.79) ,0.001
Maternal antenatal CD4 count
≥500 cells/mm
3 498 (21.0) 1.00 1.00
200–499 cells/mm
3 524 (22.1) 1.86 (1.06–3.25) 0.030 1.37 (0.77–2.46) 0.285
,200 cells/mm
3 129 (5.5) 2.47 (1.15–5.31) 0.021 1.87 (1.21–3.96) 0.009
Missing data
a 1217 (51.4) 0.54 (0.29–0.96) 0.037 0.73 (0.41–1.27) 0.267
HR, hazard ratio. aHR were adjusted for the other variables in the table. Maternal HIV status was not adjusted for in the multivariable analysis as only HIV-positive women had an
antenatal CD4 count. Note: toilet type, water source, child gender and delivery place were not signiﬁcantly associated with infant mortality.
aMissing CD4 count category includes 1179 HIV-negative women.
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This cohort study enrolled HIV-infected and -uninfected pregnant
women between 2001 and 2004 (before the availability of antiretro-
viral treatment), in rural South Africa; almost all pregnant women in
this setting present for antenatal visits (Hoque et al., 2008), and the
study enrollment rate was .80% (Bland et al., 2010). In a recent sys-
tematic review, Northern and Western Africa had, respectively, an
estimated rate of preterm births of 8.7 and 10.1%, considerably
lower compared with that in Southern Africa, at 17.5% (Beck et al.,
2010). Preterm births have multiple causes, and the design of this
study allowed us to investigate the contribution of HIV, if any, given
the enrolment of both HIV-infected and -uninfected women, in a
setting with a very high antenatal HIV prevalence estimated at
39.5% (Department of Health, 2010a,b) and high preterm delivery
rates. The prevalence of preterm deliveries was 21.4% while that of
SGA was 16.6%, with limited overlap between the two, and the ma-
ternal HIV infection was associated with a 1.2-fold increased risk of
SGA birth. This signiﬁcant association was maintained after controlling
for water source, delivery place, parity and maternal height, factors
associated with SGA in other studies (Verhoeff et al., 2001; Bhutta
et al., 2005).
SGA infants were at a signiﬁcantly increased hazard of infant mortal-
ity compared with those who were AGA, but there was no difference
in mortality between the term and preterm births. Our ﬁndings of
increased infant mortality among SGA infants are consistent with
another African study (Kasirye-Bainda and Musoke, 1992), with the
risk increasing with severity of growth restriction, such that severely
SGA infants had a 3-fold signiﬁcantly increased hazard of death
before and after adjusting for other confounders. A plausible mechan-
ism for this may be the increased post-natal morbidity rates (Kasirye-
Bainda and Musoke, 1992). As infant follow-up stopped at 2 years, we
were not able to explore longer term implications of preterm delivery,
such as developmental disabilities and cerebral palsy. Generally, there
is limited service provision for children with such problems in this
setting.
Knowledge of the independent effect of maternal HIV infection on
birth outcomes such as preterm delivery and SGA infants is needed
in order to understand the potential impact of antiretroviral treat-
ment. Additionally, quantifying the burden of neonatal and infant
morbidity and mortality associated with maternal HIV is important
in similar settings with high antenatal HIV prevalence. Our study,
conducted before antiretroviral treatment was available in this
setting, shows that maternal HIV infection was not signiﬁcantly asso-
ciated with preterm delivery, consistent with other studies in Africa
(Bulterys et al., 1994; Verhoeff et al., 2001). However, this contrast
to earlier African studies which enrolled hospital-based deliveries
only (Habib et al., 2008; Laar et al., 2010), while our study enrolled
deliveries from both in and outside hospitals. Further, in one of the
studies, 31% of pregnant women were lost prior to delivery, a large
proportion of these were HIV negative, which may affect the
strength of the association reported (Laar et al., 2010). Infants deliv-
ered at home had higher probabilities of being preterm, probably
due to the fact that these women were unable to reach a health-
care facility in time. Other independent factors associated with
preterm delivery in this and previous studies were younger maternal
age, consistent with greater perinatal risks due to social
disadvantages or biological factors (da Silva et al., 2003) and low ma-
ternal weight (Ehrenberg et al., 2003).
The current prevention of mother-to-child transmission (PMTCT)
guidelines in South Africa recommend zidovudine (AZT) from 14
weeks of pregnancy, single-dose nevirapine, 3-hourly AZT intrapartum
and a single dose of tenofovir and emtracitabine post-partum, for
women not eligible for lifelong antiretroviral treatment and antiretro-
viral treatment for those eligible starting as soon as possible in preg-
nancy (Department of Health, 2010a, b). Several studies in Europe
and the USA have reported an increased risk of preterm delivery
with antenatal highly active antiretroviral therapy (HAART), with asso-
ciations of between 1.5- and 3.5-fold increased risk (Thorne et al.,
2004; Cotter et al., 2006; Townsend et al., 2010a,b) and there are
also preliminary indications from studies in sub-Saharan Africa (SSA)
of the same association (Powis et al., 2011; van der Merwe et al.,
2011). This has been hypothesized to be due to an immunological
mechanism, with HAART in pregnancy associated with a reversal of
the Th1 to Th2 switch that is an immunological feature of normal
pregnancy (Fiore et al., 2006) rather than being caused by infant or
placental factors. Given the enormous beneﬁts of HAART for mater-
nal health and PMTCT, and the fact that most of these preterm infants
are born from gestations associated with relatively low morbidity and
mortality risk, the beneﬁts are considered to outweigh the risks in
resource-rich settings (de Ruiter et al., 2008). In a UK study, the incre-
mental risk–beneﬁt ratio of HAART compared with monotherapy
with respect to preterm delivery was modelled and it was found
that each 10 infant infections prevented through the use of antenatal
HAART would result in an additional 6 preterm births (Townsend
et al., 2010a,b).
Despite the resource-limited setting, preterm infants in our study
(37% of whom were born at 36 weeks) had good survival and we
observed no difference in the crude neonatal and infant mortality
rates comparing term and preterm deliveries. In the multivariable ana-
lysis, there was no statistically signiﬁcant difference in infant mortality
between the two groups, allowing for time-varying child infection
status, although the hazard of death was slightly higher for preterm
infants. The VTS was not designed to investigate the role of
preterm delivery in infant mortality; furthermore, the implementation
of ‘Kangaroo mother care (KMC’; continous skin-to-skin contact and
support for exclusive breastfeeding or other appropriate feeding) in
the ﬁrst week of life within the study, shown to signiﬁcantly reduce
neonatal mortality and serious morbidity amongst preterm infants in
low- and middle-income countries (Lawn et al., 2010), may have
resulted in better outcomes than would be seen in other similar set-
tings where KMC remains unavailable (Department of Health, 2008).
In the context of ongoing scale-up of antiretroviral treatment in SSA
(Mutevedzi et al., 2010), a growing number of pregnant women with
HIV will be using combination antiretroviral treatment throughout
pregnancy (Townsend et al., 2008). The beneﬁts of antenatal combin-
ation antiretroviral treatment in PMTCT in an African setting were illu-
strated in the Mma Bana trial in Botswana, with MTCT rates of 1.1%
(Shapiro et al., 2010). Maternal initiation of HAART also has beneﬁts
of increased survival chances for the woman herself (Herbst et al.,
2009) and indirectly that of her children (Ndirangu et al., 2010). Pre-
liminary indications of the same association between HAART use and
increased risk of preterm delivery in African populations as reported in
resource-rich settings (Powis et al., 2011; van der Merwe et al., 2011)
HIV, SGA and preterm births 1853highlight the need for evaluation of the potential risks as well as the
beneﬁts of antenatal HAART.
Our ﬁnding of an increased risk of SGA in infants of HIV-positive
mothers accords with previous studies elsewhere in Africa (Bulterys
et al., 1994; Taha et al., 1995), as does our identiﬁcation of primiparae
and shorter maternal height as important contributors to SGA
(Kramer, 1987a,b; Verhoeff et al., 2001; Watson-Jones et al., 2007),
together with lower socio-economic status, included here with the
use of a proxy measure (lack of piped water). Co-infections, for in-
stance malaria and other medical conditions like tuberculosis and
anaemia prior to or early in pregnancy have been shown to be import-
ant factors associated with SGA and preterm delivery (Verhoeff et al.,
2001; Noble et al., 2005; Watson-Jones et al., 2007). In this study,
such data were not available, although malaria is not an issue in
KwaZulu-Natal. We were also unable to adjust for factors such as
smoking, hypertension and anaemia.
In common with other studies reporting associations between
advanced maternal HIV disease and adverse birth outcomes (Kuhn
et al., 2005; Mehta et al., 2008), we found that HIV-positive women
with severe immunodeﬁciency had higher risk of having a SGA
infant. This raises the possibility that improving maternal health with
the use of antiretroviral treatment might result in better fetal growth
and fewer SGA infants. Although HAART regimens have been impli-
cated in preterm delivery, this does not appear to be the case for
IUGR according to a French study (Briand et al., 2009). However,
recent evidence from Botswana suggesting that maternal antiretroviral
treatment initiation before conception may be associated with very
SGA infants (Parekh et al., 2011) needs conﬁrmation, particularly
given the potential for confounding by indication due to the limited
ability to adjust for maternal disease status in this study.
In the current study of HIV-positive and -negative women, one in
ﬁve deliveries occurred preterm, but this was not associated with ma-
ternal HIV status, nor was it a risk factor for infant mortality. However,
one in six deliveries were of SGA infants and maternal HIV was one of
the factors associated with this outcome. Furthermore, SGA infants,
particularly those with HIV-positive mothers, were at increased risk
of death in the ﬁrst year of life. This has implications for clinical prac-
tice. Whereas preterm infants are usually routinely followed-up for
several months post-delivery, SGA infants are not. Our ﬁndings
suggest that SGA infants should also be included in careful clinical
follow-up to minimize morbidity and mortality. Ongoing research
and monitoring in SSA is needed to provide more information on
the complex relationships between maternal health, antenatal ART
and pregnancy outcomes in this setting where  90% of the world’s
HIV-infected pregnant women live. Future studies of preterm birth
and SGA should include variables such as hypertension, anaemia
and tuberculosis co-infections, although the feasibility of carrying out
such a study on a large rural African population is questionable.
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